Mark Hazeltine Net Worth

The estimated Net Worth of Mark Hazeltine is at least $592 millier dollars as of 2 March 2023. Mr Hazeltine owns over 3,667 units of Exagen Inc stock worth over $576,321 and over the last 4 years he sold XGN stock worth over $15,658.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Hazeltine XGN stock SEC Form 4 insiders trading

Mr has made over 3 trades of the Exagen Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 3,667 units of XGN stock worth $11,111 on 2 March 2023.

The largest trade he's ever made was selling 5,821 units of Exagen Inc stock on 8 February 2023 worth over $15,658. On average, Mr trades about 1,904 units every 109 days since 2021. As of 2 March 2023 he still owns at least 190,205 units of Exagen Inc stock.

You can see the complete history of Mr Hazeltine stock trades at the bottom of the page.

Mr. Mark Hazeltine biography

Mark Hazeltine is the Chief Operating Officer at Exagen Inc.

How old is Mr Hazeltine?

Mr Hazeltine is 47, he's been the Chief Operating Officer of Exagen Inc since . There are 10 older and 4 younger executives at Exagen Inc. The oldest executive at Exagen Inc is James Tullis, 72, who is the Independent Director.

What's Mr Hazeltine's mailing address?

Mark's mailing address filed with the SEC is C/O EXAGEN INC., 1261 LIBERTY WAY, VISTA, CA, 92081.

Insiders trading at Exagen Inc

Over the last 5 years, insiders at Exagen Inc have traded over $8,628,989 worth of Exagen Inc stock and bought 556,568 units worth $6,283,309 . The most active insiders traders include James L L Tullis, Bio Exagen, L.P.H.I.G. Gpii... et Jeffrey Thomas Elliott. On average, Exagen Inc executives and independent directors trade stock every 48 days with the average trade being worth of $109,189. The most recent stock trade was executed by John Aballi on 16 May 2024, trading 40,401 units of XGN stock currently worth $77,570.

What does Exagen Inc do?

exagen diagnostics, inc. is a patient focused, discovery driven, clia-certified, cap-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of rheumatology and autoimmune diseases. committed to personalized medicine, our avise tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. for more information on our company, please visit www.exagen.com. for more information on avise testing services, please visit www.avisetest.com.

Complete history of Mr Hazeltine stock trades at Exagen Inc

Exagen Inc executives and stock owners

Exagen Inc executives and other stock owners filed with the SEC include:

• Fortunato Rocca,
  President, Chief Executive Officer and Director
• Fortunato Rocca,
  CEO, Pres & Director
• Kamal Adawi M.S., MBA,
  CFO & Corp. Sec.
• Dr. Debra Jeske Zack,
  Chief Medical Officer
• Kamal Adawi,
  Chief Financial Officer and Corporate Secretary
• Jeffrey Elliott,
  Independent Director
• Tina Nova,
  Independent Director
• Chet Burrell,
  Independent Director
• Brian Birk,
  Independent Chairman of the Board
• Bruce Robertson,
  Independent Director
• James Tullis,
  Independent Director
• Ebetuel Pallares,
  Independent Director
• Wendy Johnson,
  Independent Director
• Debra Zack,
  Chief Medical Officer
• Anja Kammesheidt,
  Chief Scientific Officer
• John Wegener,
  Sr. VP of Sales and Marketing
• Dr. Ming-Chou Lee Ph.D.,
  Chief Technology Officer
• Mark Hazeltine,
  Chief Operating Officer
• Frank Stokes,
  Director
• Scott D Kahn,
  Director
• Thierry Dervieux,
  Chief Scientific Officer
• James L Ltullis Growth Fund...,
  
• Bio Exagen, L.P.H.I.G. Gpii...,
  
• Dickerson Capital Focus Iii...,
  
• Holdings Limited Partnershi...,
  
• Co Investment Fund, L.P.Nms...,
  
• Paul Kim,
  Director
• Co Investment Fund, L.P.Sun...,
  
• Ana Hooker,
  Director
• John Aballi,
  President and CEO
• Mark Hazeltine,
  Chief Business Officer
• Jeffrey G. Black,
  Chief Financial Officer